NO318978B1 - Substituerte dihydroindolderivater, farmasoytiske sammensetninger inneholdende dem og deres anvendelse. - Google Patents

Substituerte dihydroindolderivater, farmasoytiske sammensetninger inneholdende dem og deres anvendelse. Download PDF

Info

Publication number: NO318978B1
Authority: NO; Norway
Prior art keywords: compound according; group; hydrogen; indole; bond
Prior art date: 1996-12-20

Application number

NO19992895A

Other languages

English (en)

Norwegian (no)

Other versions

NO992895D0 (no

NO992895L (no

Inventor

Henrik Pedersen

Jens Kristian Perregaard

Benny Bang-Andersen

Ivan Mikkelsen

Robert Dancer

Original Assignee

Lundbeck & Co As H

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-12-20

Filing date

1999-06-14

Publication date

2005-05-30

1999-06-14 Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H

1999-06-14 Publication of NO992895D0 publication Critical patent/NO992895D0/no

1999-08-13 Publication of NO992895L publication Critical patent/NO992895L/no

2005-05-30 Publication of NO318978B1 publication Critical patent/NO318978B1/no

Links

LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical class C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 title claims description 22
239000008194 pharmaceutical composition Chemical class 0.000 title claims description 6
150000001875 compounds Chemical class 0.000 claims description 151
229910052739 hydrogen Inorganic materials 0.000 claims description 36
239000001257 hydrogen Substances 0.000 claims description 36
150000002431 hydrogen Chemical class 0.000 claims description 24
229910052736 halogen Inorganic materials 0.000 claims description 22
150000002367 halogens Chemical class 0.000 claims description 22
238000011282 treatment Methods 0.000 claims description 19
230000000694 effects Effects 0.000 claims description 17
239000000460 chlorine Substances 0.000 claims description 14
-1 dihydroindole compound Chemical class 0.000 claims description 14
125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 12
150000003839 salts Chemical class 0.000 claims description 12
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
125000004093 cyano group Chemical group *C#N 0.000 claims description 10
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 10
125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 9
239000002253 acid Substances 0.000 claims description 9
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 8
239000003814 drug Substances 0.000 claims description 8
208000019901 Anxiety disease Diseases 0.000 claims description 7
208000028017 Psychotic disease Diseases 0.000 claims description 7
125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 6
201000000980 schizophrenia Diseases 0.000 claims description 6
208000024891 symptom Diseases 0.000 claims description 6
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
208000019695 Migraine disease Diseases 0.000 claims description 5
230000016571 aggressive behavior Effects 0.000 claims description 5
239000003085 diluting agent Substances 0.000 claims description 5
206010027599 migraine Diseases 0.000 claims description 5
208000007848 Alcoholism Diseases 0.000 claims description 4
208000024827 Alzheimer disease Diseases 0.000 claims description 4
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 claims description 4
208000030990 Impulse-control disease Diseases 0.000 claims description 4
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 4
206010039966 Senile dementia Diseases 0.000 claims description 4
206010001584 alcohol abuse Diseases 0.000 claims description 4
208000025746 alcohol use disease Diseases 0.000 claims description 4
125000000217 alkyl group Chemical group 0.000 claims description 4
239000000164 antipsychotic agent Substances 0.000 claims description 4
229910052801 chlorine Inorganic materials 0.000 claims description 4
208000023589 ischemic disease Diseases 0.000 claims description 4
125000001624 naphthyl group Chemical group 0.000 claims description 4
208000019906 panic disease Diseases 0.000 claims description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
208000024172 Cardiovascular disease Diseases 0.000 claims description 3
208000011688 Generalised anxiety disease Diseases 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
208000029364 generalized anxiety disease Diseases 0.000 claims description 3
125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 2
229910002091 carbon monoxide Inorganic materials 0.000 claims description 2
125000005146 naphthylsulfonyl group Chemical group C1(=CC=CC2=CC=CC=C12)S(=O)(=O)* 0.000 claims description 2
125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 2
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
229940005529 antipsychotics Drugs 0.000 claims 1
239000000203 mixture Substances 0.000 description 86
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 82
239000000243 solution Substances 0.000 description 58
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 54
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 50
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 45
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 37
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 29
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 28
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 28
235000019439 ethyl acetate Nutrition 0.000 description 28
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 25
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 24
238000005481 NMR spectroscopy Methods 0.000 description 24
239000000741 silica gel Substances 0.000 description 24
229910002027 silica gel Inorganic materials 0.000 description 24
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 22
239000003921 oil Substances 0.000 description 19
235000019198 oils Nutrition 0.000 description 19
108090000357 Dopamine D4 receptors Proteins 0.000 description 16
102000003962 Dopamine D4 receptors Human genes 0.000 description 16
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 16
239000002904 solvent Substances 0.000 description 16
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 15
239000013067 intermediate product Substances 0.000 description 15
238000000034 method Methods 0.000 description 15
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 14
239000000047 product Substances 0.000 description 13
239000008346 aqueous phase Substances 0.000 description 12
239000012043 crude product Substances 0.000 description 12
102000005962 receptors Human genes 0.000 description 12
108020003175 receptors Proteins 0.000 description 12
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 11
229960000583 acetic acid Drugs 0.000 description 10
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 10
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 10
238000010992 reflux Methods 0.000 description 10
235000011054 acetic acid Nutrition 0.000 description 9
239000011541 reaction mixture Substances 0.000 description 9
230000009467 reduction Effects 0.000 description 9
239000000556 agonist Substances 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 8
229960003638 dopamine Drugs 0.000 description 8
239000012074 organic phase Substances 0.000 description 8
238000000746 purification Methods 0.000 description 8
238000003756 stirring Methods 0.000 description 8
239000000725 suspension Substances 0.000 description 8
238000012360 testing method Methods 0.000 description 8
238000010626 work up procedure Methods 0.000 description 8
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 7
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 7
239000000908 ammonium hydroxide Substances 0.000 description 7
239000013078 crystal Substances 0.000 description 7
239000000284 extract Substances 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 7
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 6
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 6
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
238000004440 column chromatography Methods 0.000 description 6
238000001816 cooling Methods 0.000 description 6
229940079593 drug Drugs 0.000 description 6
239000003480 eluent Substances 0.000 description 6
DEQYTNZJHKPYEZ-UHFFFAOYSA-N ethyl acetate;heptane Chemical compound CCOC(C)=O.CCCCCCC DEQYTNZJHKPYEZ-UHFFFAOYSA-N 0.000 description 6
238000001914 filtration Methods 0.000 description 6
239000003446 ligand Substances 0.000 description 6
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
210000004515 ventral tegmental area Anatomy 0.000 description 6
102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 5
102000004980 Dopamine D2 Receptors Human genes 0.000 description 5
108090001111 Dopamine D2 Receptors Proteins 0.000 description 5
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 5
UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 5
239000012267 brine Substances 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
230000002401 inhibitory effect Effects 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 4
DQGWEDRPBNHZDE-UHFFFAOYSA-N 6-chloro-3-(1,2,3,6-tetrahydropyridin-4-yl)-1h-indole Chemical compound C=1NC2=CC(Cl)=CC=C2C=1C1=CCNCC1 DQGWEDRPBNHZDE-UHFFFAOYSA-N 0.000 description 4
229910010082 LiAlH Inorganic materials 0.000 description 4
PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 4
239000012346 acetyl chloride Substances 0.000 description 4
239000000654 additive Substances 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
239000005557 antagonist Substances 0.000 description 4
230000000561 anti-psychotic effect Effects 0.000 description 4
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
239000012458 free base Substances 0.000 description 4
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 4
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
239000012047 saturated solution Substances 0.000 description 4
230000000862 serotonergic effect Effects 0.000 description 4
239000007787 solid Substances 0.000 description 4
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
REKVGPTYHRAVGP-UHFFFAOYSA-N 1,2-dimethyl-3-propan-2-yloxybenzene Chemical compound CC(C)OC1=CC=CC(C)=C1C REKVGPTYHRAVGP-UHFFFAOYSA-N 0.000 description 3
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
101150104779 HTR2A gene Proteins 0.000 description 3
229910010084 LiAlH4 Inorganic materials 0.000 description 3
239000012359 Methanesulfonyl chloride Substances 0.000 description 3
102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 3
108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
230000029936 alkylation Effects 0.000 description 3
238000005804 alkylation reaction Methods 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
229910052794 bromium Inorganic materials 0.000 description 3
230000005587 bubbling Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000001035 drying Methods 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
235000019253 formic acid Nutrition 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
239000012442 inert solvent Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
150000002500 ions Chemical class 0.000 description 3
239000012280 lithium aluminium hydride Substances 0.000 description 3
239000012528 membrane Substances 0.000 description 3
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
210000001577 neostriatum Anatomy 0.000 description 3
210000002569 neuron Anatomy 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 3
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
230000000698 schizophrenic effect Effects 0.000 description 3
229940076279 serotonin Drugs 0.000 description 3
238000001228 spectrum Methods 0.000 description 3
ZCKGEIMZHXXIAL-UHFFFAOYSA-N 1,2-bis(bromomethyl)-3-propan-2-yloxybenzene Chemical compound CC(C)OC1=CC=CC(CBr)=C1CBr ZCKGEIMZHXXIAL-UHFFFAOYSA-N 0.000 description 2
HBOBUTXJMIXYPE-UHFFFAOYSA-N 1,2-bis(chloromethyl)-4,5-dimethoxybenzene Chemical compound COC1=CC(CCl)=C(CCl)C=C1OC HBOBUTXJMIXYPE-UHFFFAOYSA-N 0.000 description 2
238000005160 1H NMR spectroscopy Methods 0.000 description 2
QWBBPBRQALCEIZ-UHFFFAOYSA-N 2,3-dimethylphenol Chemical compound CC1=CC=CC(O)=C1C QWBBPBRQALCEIZ-UHFFFAOYSA-N 0.000 description 2
GATUUSFIQPRJQV-UHFFFAOYSA-N 2-(2-iodoethyl)-2,3-dihydro-1h-indene Chemical compound C1=CC=C2CC(CCI)CC2=C1 GATUUSFIQPRJQV-UHFFFAOYSA-N 0.000 description 2
AODIFCDICXVRQN-UHFFFAOYSA-N 3-(hydroxymethyl)-2,3-dihydro-1h-indene-5-carbonitrile Chemical compound C1=C(C#N)C=C2C(CO)CCC2=C1 AODIFCDICXVRQN-UHFFFAOYSA-N 0.000 description 2
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
108010072564 5-HT2A Serotonin Receptor Proteins 0.000 description 2
102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 description 2
101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 description 2
XRSHRVUSZINCGX-UHFFFAOYSA-N 6-chloro-1-(1,2,3,6-tetrahydropyridin-4-yl)indole Chemical compound C12=CC(Cl)=CC=C2C=CN1C1=CCNCC1 XRSHRVUSZINCGX-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
208000012902 Nervous system disease Diseases 0.000 description 2
208000025966 Neurological disease Diseases 0.000 description 2
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
230000002152 alkylating effect Effects 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
238000010171 animal model Methods 0.000 description 2
239000000935 antidepressant agent Substances 0.000 description 2
230000036506 anxiety Effects 0.000 description 2
239000002249 anxiolytic agent Substances 0.000 description 2
230000000949 anxiolytic effect Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000002585 base Substances 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
238000009835 boiling Methods 0.000 description 2
LRJRPHROCLHMHK-UHFFFAOYSA-N boron;n,n-dimethylmethanamine Chemical compound [B].CN(C)C LRJRPHROCLHMHK-UHFFFAOYSA-N 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000004296 chiral HPLC Methods 0.000 description 2
230000002301 combined effect Effects 0.000 description 2
DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
230000000706 effect on dopamine Effects 0.000 description 2
LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 2
238000009472 formulation Methods 0.000 description 2
238000013467 fragmentation Methods 0.000 description 2
238000006062 fragmentation reaction Methods 0.000 description 2
229960003878 haloperidol Drugs 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
239000012948 isocyanate Substances 0.000 description 2
150000002513 isocyanates Chemical class 0.000 description 2
TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
HSZCZNFXUDYRKD-UHFFFAOYSA-M lithium iodide Chemical compound [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
ILPJITNIMGVOHA-UHFFFAOYSA-N n,n-diethylethanamine;ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O.CCN(CC)CC ILPJITNIMGVOHA-UHFFFAOYSA-N 0.000 description 2
229910017604 nitric acid Inorganic materials 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
150000004885 piperazines Chemical class 0.000 description 2
125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000002243 precursor Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
235000019260 propionic acid Nutrition 0.000 description 2
229940095574 propionic acid Drugs 0.000 description 2
208000020016 psychiatric disease Diseases 0.000 description 2
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
239000011734 sodium Substances 0.000 description 2
MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 2
229950001675 spiperone Drugs 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 2
238000004885 tandem mass spectrometry Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
FBTZMAUPYYNVPM-UHFFFAOYSA-M (2-aminophenyl)methyl-triphenylphosphanium;bromide Chemical compound [Br-].NC1=CC=CC=C1C[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 FBTZMAUPYYNVPM-UHFFFAOYSA-M 0.000 description 1
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
TVBDOIGBKMFAEW-UHFFFAOYSA-N (6-bromo-2,3-dihydro-1h-inden-1-yl)methanol Chemical compound C1=C(Br)C=C2C(CO)CCC2=C1 TVBDOIGBKMFAEW-UHFFFAOYSA-N 0.000 description 1
PUYMSXSJNKMVIU-UHFFFAOYSA-N (6-cyano-2,3-dihydro-1h-inden-1-yl)methyl methanesulfonate Chemical compound C1=C(C#N)C=C2C(COS(=O)(=O)C)CCC2=C1 PUYMSXSJNKMVIU-UHFFFAOYSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
RYGAENQWIQPFAI-UHFFFAOYSA-N 1,3-dihydroindene-2,2-dicarboxylic acid Chemical compound C1=CC=C2CC(C(=O)O)(C(O)=O)CC2=C1 RYGAENQWIQPFAI-UHFFFAOYSA-N 0.000 description 1
IXKUXGGVAMQWFE-UHFFFAOYSA-N 1-[2-[2-[4-(6-chloro-1h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]ethyl]-2,3-dihydroindol-1-yl]ethanone Chemical compound C1C2=CC=CC=C2N(C(=O)C)C1CCN1CC=C(C=2C3=CC=C(Cl)C=C3NC=2)CC1 IXKUXGGVAMQWFE-UHFFFAOYSA-N 0.000 description 1
ZNTWDJJVTSYGTC-UHFFFAOYSA-N 1-[2-[[4-(6-chloro-1h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]methyl]-2,3-dihydroindol-1-yl]ethanone Chemical compound C1C2=CC=CC=C2N(C(=O)C)C1CN1CC=C(C=2C3=CC=C(Cl)C=C3NC=2)CC1 ZNTWDJJVTSYGTC-UHFFFAOYSA-N 0.000 description 1
LIHLMGUFQGWPEJ-UHFFFAOYSA-N 1-[2-[[4-(6-chloro-1h-indol-3-yl)piperidin-1-yl]methyl]-2,3-dihydroindol-1-yl]ethanone Chemical compound C1C2=CC=CC=C2N(C(=O)C)C1CN1CCC(C=2C3=CC=C(Cl)C=C3NC=2)CC1 LIHLMGUFQGWPEJ-UHFFFAOYSA-N 0.000 description 1
OCQCPYAUFFHSLW-UHFFFAOYSA-N 1-[3-(2-methylsulfonylethyl)-2,3-dihydroindol-1-yl]ethanone Chemical compound C1=CC=C2N(C(=O)C)CC(CCS(C)(=O)=O)C2=C1 OCQCPYAUFFHSLW-UHFFFAOYSA-N 0.000 description 1
BCPUFBGXDLYTNE-UHFFFAOYSA-N 1-[3-[2-[4-(1h-indol-5-yl)piperazin-1-yl]ethyl]-2,3-dihydroindol-1-yl]ethanone Chemical compound C12=CC=CC=C2N(C(=O)C)CC1CCN1CCN(C=2C=C3C=CNC3=CC=2)CC1 BCPUFBGXDLYTNE-UHFFFAOYSA-N 0.000 description 1
QPGSWIJJPCCSSU-UHFFFAOYSA-N 1-[3-[2-[4-(6,7-dichloro-1h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]ethyl]-2,3-dihydroindol-1-yl]ethanone Chemical compound C12=CC=CC=C2N(C(=O)C)CC1CCN1CC=C(C=2C3=CC=C(Cl)C(Cl)=C3NC=2)CC1 QPGSWIJJPCCSSU-UHFFFAOYSA-N 0.000 description 1
PAEDXTDHOMVAIK-UHFFFAOYSA-N 1-[3-[2-[4-(6-chloro-1h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]ethyl]-5-fluoro-2,3-dihydroindol-1-yl]ethanone Chemical compound C12=CC(F)=CC=C2N(C(=O)C)CC1CCN1CC=C(C=2C3=CC=C(Cl)C=C3NC=2)CC1 PAEDXTDHOMVAIK-UHFFFAOYSA-N 0.000 description 1
RQBUPPSGZDLXGZ-UHFFFAOYSA-N 1-[3-[2-[4-(6-chloro-1h-indol-3-yl)piperazin-1-yl]ethyl]-5-fluoro-2,3-dihydroindol-1-yl]ethanone Chemical compound C12=CC(F)=CC=C2N(C(=O)C)CC1CCN1CCN(C=2C3=CC=C(Cl)C=C3NC=2)CC1 RQBUPPSGZDLXGZ-UHFFFAOYSA-N 0.000 description 1
MTTYYGXGDHEQBG-UHFFFAOYSA-N 1-[3-[2-[4-(6-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-2,3-dihydroindol-1-yl]ethanone Chemical compound C12=CC=CC=C2N(C(=O)C)CC1CCN1CCC(C=2C3=CC=C(Cl)C=C3NC=2)CC1 MTTYYGXGDHEQBG-UHFFFAOYSA-N 0.000 description 1
PZSWVAZWLTZBOP-UHFFFAOYSA-N 1-[3-[4-[4-(6-chloro-1h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]butyl]-2,3-dihydroindol-1-yl]ethanone Chemical compound C12=CC=CC=C2N(C(=O)C)CC1CCCCN1CC=C(C=2C3=CC=C(Cl)C=C3NC=2)CC1 PZSWVAZWLTZBOP-UHFFFAOYSA-N 0.000 description 1
FDYQYYHTNJDDSG-UHFFFAOYSA-N 1-[5-bromo-3-(2-methylsulfonylethyl)-2,3-dihydroindol-1-yl]ethanone Chemical compound BrC1=CC=C2N(C(=O)C)CC(CCS(C)(=O)=O)C2=C1 FDYQYYHTNJDDSG-UHFFFAOYSA-N 0.000 description 1
HGFNZCHJCKIMDH-UHFFFAOYSA-N 1-[5-fluoro-3-[2-[4-(1h-indol-4-yl)piperazin-1-yl]ethyl]-2,3-dihydroindol-1-yl]ethanone Chemical compound C12=CC(F)=CC=C2N(C(=O)C)CC1CCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 HGFNZCHJCKIMDH-UHFFFAOYSA-N 0.000 description 1
XUDCMQBOWOLYCF-UHFFFAOYSA-N 2,3-dihydro-1h-indene-2-carboxylic acid Chemical compound C1=CC=C2CC(C(=O)O)CC2=C1 XUDCMQBOWOLYCF-UHFFFAOYSA-N 0.000 description 1
HCYFGRCYSCXKNQ-UHFFFAOYSA-N 2-(1,3-dimethyl-2,6-dioxo-7-purinyl)acetic acid Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)=O)C=N2 HCYFGRCYSCXKNQ-UHFFFAOYSA-N 0.000 description 1
SSJGMHHEVDFMJM-UHFFFAOYSA-N 2-(2,3-dihydro-1h-inden-2-yl)ethanol Chemical compound C1=CC=C2CC(CCO)CC2=C1 SSJGMHHEVDFMJM-UHFFFAOYSA-N 0.000 description 1
JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
MXTYSYXDDDVPBQ-UHFFFAOYSA-N 2-(5-fluoro-1h-indol-3-yl)ethanol Chemical compound C1=C(F)C=C2C(CCO)=CNC2=C1 MXTYSYXDDDVPBQ-UHFFFAOYSA-N 0.000 description 1
PPVKBEWRGPFIIJ-UHFFFAOYSA-N 2-[1-[(2-methylpropan-2-yl)oxycarbonyl]-2,3-dihydroindol-3-yl]acetic acid Chemical compound C1=CC=C2N(C(=O)OC(C)(C)C)CC(CC(O)=O)C2=C1 PPVKBEWRGPFIIJ-UHFFFAOYSA-N 0.000 description 1
NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
BKFSUZNMFPCJNJ-UHFFFAOYSA-N 2-hydroxy-3,4-dimethylidenecyclohexa-1,5-diene-1-carboxylic acid Chemical compound OC(=O)C=1C=CC(=C)C(=C)C=1O BKFSUZNMFPCJNJ-UHFFFAOYSA-N 0.000 description 1
FBCZWQNVHNIQOD-UHFFFAOYSA-N 2-piperazin-1-yl-1h-indole Chemical class C1CNCCN1C1=CC2=CC=CC=C2N1 FBCZWQNVHNIQOD-UHFFFAOYSA-N 0.000 description 1
VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
QNPOFWUESHOMOE-UHFFFAOYSA-N 3,6,7,8-tetrahydrocyclopenta[e]indole-8-carboxylic acid Chemical compound C1=C2NC=CC2=C2C(C(=O)O)CCC2=C1 QNPOFWUESHOMOE-UHFFFAOYSA-N 0.000 description 1
YYGRBGDXCCDNHR-UHFFFAOYSA-N 3-(piperidin-1-ylmethyl)-2h-indazole Chemical class N1N=C2C=CC=CC2=C1CN1CCCCC1 YYGRBGDXCCDNHR-UHFFFAOYSA-N 0.000 description 1
FPCCSQOGAWCVBH-PSQIVULCSA-N 3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]-1,1,2,2-tetratritioethyl]-1h-quinazoline-2,4-dione Chemical compound O=C1NC2=CC=CC=C2C(=O)N1C([3H])([3H])C([3H])([3H])N(CC1)CCC1C(=O)C1=CC=C(F)C=C1 FPCCSQOGAWCVBH-PSQIVULCSA-N 0.000 description 1
QCOZTKHZGPBVAO-UHFFFAOYSA-N 3-[2-[4-(6-chloro-1h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]ethyl]-2,3-dihydroindole-1-carbaldehyde Chemical compound C1N(C=O)C2=CC=CC=C2C1CCN(CC1)CC=C1C1=CNC2=CC(Cl)=CC=C21 QCOZTKHZGPBVAO-UHFFFAOYSA-N 0.000 description 1
LSPWEPZMKDQHPN-UHFFFAOYSA-N 3-[2-[4-(6-chloro-1h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]ethyl]-n-methylsulfonyl-2,3-dihydroindole-1-carboxamide Chemical compound C12=CC=CC=C2N(C(=O)NS(=O)(=O)C)CC1CCN1CC=C(C=2C3=CC=C(Cl)C=C3NC=2)CC1 LSPWEPZMKDQHPN-UHFFFAOYSA-N 0.000 description 1
RYNJRSWUUHSFBB-UHFFFAOYSA-N 3-[2-[4-(6-chloro-1h-indol-3-yl)piperidin-1-yl]ethyl]-2,3-dihydroindole-1-carbaldehyde Chemical compound C1N(C=O)C2=CC=CC=C2C1CCN(CC1)CCC1C1=CNC2=CC(Cl)=CC=C21 RYNJRSWUUHSFBB-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
INUNLMUAPJVRME-UHFFFAOYSA-N 3-chloropropanoyl chloride Chemical compound ClCCC(Cl)=O INUNLMUAPJVRME-UHFFFAOYSA-N 0.000 description 1
BLFSIQLJZNHYNW-UHFFFAOYSA-N 4-[4-(6-chloro-1h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]-1-(2,3-dihydroindol-1-yl)butan-1-one Chemical compound C1CC2=CC=CC=C2N1C(=O)CCCN(CC1)CC=C1C1=CNC2=CC(Cl)=CC=C21 BLFSIQLJZNHYNW-UHFFFAOYSA-N 0.000 description 1
DZSQTSBXFLYELY-UHFFFAOYSA-N 4-[[4-(6-chloro-1h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]methyl]-1,4,5,6-tetrahydrocyclopenta[e]indole Chemical compound C=1NC2=CC(Cl)=CC=C2C=1C(CC1)=CCN1CC(C1=C2CC=N1)CC1=C2C=CC1 DZSQTSBXFLYELY-UHFFFAOYSA-N 0.000 description 1
MPZMVUQGXAOJIK-UHFFFAOYSA-N 4-bromopyridine;hydron;chloride Chemical compound Cl.BrC1=CC=NC=C1 MPZMVUQGXAOJIK-UHFFFAOYSA-N 0.000 description 1
102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
108091005479 5-HT2 receptors Proteins 0.000 description 1
ODFFPRGJZRXNHZ-UHFFFAOYSA-N 5-fluoroindole Chemical compound FC1=CC=C2NC=CC2=C1 ODFFPRGJZRXNHZ-UHFFFAOYSA-N 0.000 description 1
MZILCLREQQTZJP-UHFFFAOYSA-N 5-piperazin-1-yl-1h-indole Chemical compound C1CNCCN1C1=CC=C(NC=C2)C2=C1 MZILCLREQQTZJP-UHFFFAOYSA-N 0.000 description 1
UWHWAXCLSNQVAG-UHFFFAOYSA-N 6,7-dichloro-1h-indole Chemical compound ClC1=CC=C2C=CNC2=C1Cl UWHWAXCLSNQVAG-UHFFFAOYSA-N 0.000 description 1
TUUMQUDGSNYPKL-UHFFFAOYSA-N 6-chloro-3-[1-[2-(2,3-dihydro-1h-indol-3-yl)ethyl]-3,6-dihydro-2h-pyridin-4-yl]-1h-indole Chemical compound C1NC2=CC=CC=C2C1CCN(CC1)CC=C1C1=CNC2=CC(Cl)=CC=C21 TUUMQUDGSNYPKL-UHFFFAOYSA-N 0.000 description 1
MJPPXMBLTKLPIT-UHFFFAOYSA-N 6-chloro-3-[1-[2-(2,3-dihydroindol-1-yl)ethyl]piperidin-4-yl]-1h-indole Chemical compound C1CC2=CC=CC=C2N1CCN(CC1)CCC1C1=CNC2=CC(Cl)=CC=C21 MJPPXMBLTKLPIT-UHFFFAOYSA-N 0.000 description 1
YGCFALCFICDDHC-UHFFFAOYSA-N 6-chloro-3-[1-[4-(2,3-dihydro-1h-indol-3-yl)butyl]-3,6-dihydro-2h-pyridin-4-yl]-1h-indole Chemical compound C1NC2=CC=CC=C2C1CCCCN(CC1)CC=C1C1=CNC2=CC(Cl)=CC=C21 YGCFALCFICDDHC-UHFFFAOYSA-N 0.000 description 1
HNZRMACEYYMLRX-UHFFFAOYSA-N 6-chloro-3-[1-[4-(2,3-dihydroindol-1-yl)butyl]-3,6-dihydro-2h-pyridin-4-yl]-1h-indole Chemical compound C1CC2=CC=CC=C2N1CCCCN(CC1)CC=C1C1=CNC2=CC(Cl)=CC=C21 HNZRMACEYYMLRX-UHFFFAOYSA-N 0.000 description 1
WMYQAKANKREQLM-UHFFFAOYSA-N 7-chloro-1h-indole Chemical compound ClC1=CC=CC2=C1NC=C2 WMYQAKANKREQLM-UHFFFAOYSA-N 0.000 description 1
PCVWLBUECBSQPD-UHFFFAOYSA-N 7-methyl-2,3-dihydro-1h-indene-1-carboxylic acid Chemical compound CC1=CC=CC2=C1C(C(O)=O)CC2 PCVWLBUECBSQPD-UHFFFAOYSA-N 0.000 description 1
DNUXLYCNEUZECP-UHFFFAOYSA-N 7-methyl-3-oxo-1,2-dihydroindene-1-carboxylic acid Chemical compound CC1=CC=CC2=C1C(C(O)=O)CC2=O DNUXLYCNEUZECP-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical compound C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 description 1
SKTFQHRVFFOHTQ-UHFFFAOYSA-N 8-bromo-1,3-dimethyl-7h-purine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Br)=N2 SKTFQHRVFFOHTQ-UHFFFAOYSA-N 0.000 description 1
206010002869 Anxiety symptoms Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
201000006474 Brain Ischemia Diseases 0.000 description 1
101100240520 Caenorhabditis elegans nhr-14 gene Proteins 0.000 description 1
208000009132 Catalepsy Diseases 0.000 description 1
206010008120 Cerebral ischaemia Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
101150049660 DRD2 gene Proteins 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
206010054089 Depressive symptom Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
102000015554 Dopamine receptor Human genes 0.000 description 1
108050004812 Dopamine receptor Proteins 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
102000017911 HTR1A Human genes 0.000 description 1
101150015707 HTR1A gene Proteins 0.000 description 1
101000865206 Homo sapiens D(4) dopamine receptor Proteins 0.000 description 1
OWIKHYCFFJSOEH-UHFFFAOYSA-N Isocyanic acid Chemical class N=C=O OWIKHYCFFJSOEH-UHFFFAOYSA-N 0.000 description 1
238000003109 Karl Fischer titration Methods 0.000 description 1
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
239000004367 Lipase Substances 0.000 description 1
102000004882 Lipase Human genes 0.000 description 1
108090001060 Lipase Proteins 0.000 description 1
241001661345 Moesziomyces antarcticus Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
235000019502 Orange oil Nutrition 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
206010037180 Psychiatric symptoms Diseases 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
206010047853 Waxy flexibility Diseases 0.000 description 1
201000002380 X-linked amelogenesis imperfecta hypoplastic/hypomaturation 2 Diseases 0.000 description 1
HYBHEYPBUQFHJR-UHFFFAOYSA-N [4-(6-chloro-1h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]-(3,6,7,8-tetrahydrocyclopenta[e]indol-8-yl)methanone Chemical compound C1CC2=CC=C3NC=CC3=C2C1C(=O)N(CC1)CC=C1C1=CNC2=CC(Cl)=CC=C21 HYBHEYPBUQFHJR-UHFFFAOYSA-N 0.000 description 1
YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
229950003769 acefylline Drugs 0.000 description 1
RWFPXJAUVOBOLJ-UHFFFAOYSA-N acetic acid;ethyl acetate;heptane Chemical compound CC(O)=O.CCOC(C)=O.CCCCCCC RWFPXJAUVOBOLJ-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
230000001270 agonistic effect Effects 0.000 description 1
229910000086 alane Inorganic materials 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
229960004050 aminobenzoic acid Drugs 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000002539 anti-aggressive effect Effects 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
229940005530 anxiolytics Drugs 0.000 description 1
125000004350 aryl cycloalkyl group Chemical group 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
238000003556 assay Methods 0.000 description 1
238000010533 azeotropic distillation Methods 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
235000019400 benzoyl peroxide Nutrition 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000031709 bromination Effects 0.000 description 1
238000005893 bromination reaction Methods 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
210000001638 cerebellum Anatomy 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
150000001793 charged compounds Chemical class 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
229930016911 cinnamic acid Natural products 0.000 description 1
235000013985 cinnamic acid Nutrition 0.000 description 1
HNEGQIOMVPPMNR-IHWYPQMZSA-N citraconic acid Chemical compound OC(=O)C(/C)=C\C(O)=O HNEGQIOMVPPMNR-IHWYPQMZSA-N 0.000 description 1
229940018557 citraconic acid Drugs 0.000 description 1
229960004106 citric acid Drugs 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
229960004170 clozapine Drugs 0.000 description 1
238000004040 coloring Methods 0.000 description 1
229940126086 compound 21 Drugs 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000003001 depressive effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 1
UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
239000008098 formaldehyde solution Substances 0.000 description 1
230000022244 formylation Effects 0.000 description 1
238000006170 formylation reaction Methods 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
239000000174 gluconic acid Substances 0.000 description 1
229950006191 gluconic acid Drugs 0.000 description 1
235000012208 gluconic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
229960002989 glutamic acid Drugs 0.000 description 1
229960004275 glycolic acid Drugs 0.000 description 1
230000002140 halogenating effect Effects 0.000 description 1
230000026030 halogenation Effects 0.000 description 1
238000005658 halogenation reaction Methods 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
239000005457 ice water Substances 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
125000004130 indan-2-yl group Chemical group [H]C1=C([H])C([H])=C2C(=C1[H])C([H])([H])C([H])(*)C2([H])[H] 0.000 description 1
239000003617 indole-3-acetic acid Substances 0.000 description 1
150000002475 indoles Chemical class 0.000 description 1
125000001041 indolyl group Chemical class 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
229960005417 ketanserin Drugs 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
229960000448 lactic acid Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960004502 levodopa Drugs 0.000 description 1
235000019421 lipase Nutrition 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
229940099690 malic acid Drugs 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 description 1
WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000012452 mother liquor Substances 0.000 description 1
LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
MUMVIYLVHVCYGI-UHFFFAOYSA-N n,n,n',n',n",n"-hexamethylmethanetriamine Chemical compound CN(C)C(N(C)C)N(C)C MUMVIYLVHVCYGI-UHFFFAOYSA-N 0.000 description 1
PQSOLLURQXDZSZ-UHFFFAOYSA-N n,n-diethylethanamine;ethyl acetate;methanol Chemical compound OC.CCOC(C)=O.CCN(CC)CC PQSOLLURQXDZSZ-UHFFFAOYSA-N 0.000 description 1
VSPPONOIKZXUBJ-UHFFFAOYSA-N n,n-diethylethanamine;oxolane Chemical compound C1CCOC1.CCN(CC)CC VSPPONOIKZXUBJ-UHFFFAOYSA-N 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
101150006061 neur gene Proteins 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
230000000324 neuroprotective effect Effects 0.000 description 1
230000000802 nitrating effect Effects 0.000 description 1
150000002828 nitro derivatives Chemical class 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
BTFQKIATRPGRBS-UHFFFAOYSA-N o-tolualdehyde Chemical compound CC1=CC=CC=C1C=O BTFQKIATRPGRBS-UHFFFAOYSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000010502 orange oil Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
150000003891 oxalate salts Chemical class 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
239000004031 partial agonist Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
238000003825 pressing Methods 0.000 description 1
230000003518 presynaptic effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
239000012070 reactive reagent Substances 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
238000011808 rodent model Methods 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 description 1
230000003860 sleep quality Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
239000012258 stirred mixture Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
210000003568 synaptosome Anatomy 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
229960001367 tartaric acid Drugs 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000003441 thioacyl group Chemical group 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
ABDKAPXRBAPSQN-UHFFFAOYSA-N veratrole Chemical compound COC1=CC=CC=C1OC ABDKAPXRBAPSQN-UHFFFAOYSA-N 0.000 description 1
239000011592 zinc chloride Substances 0.000 description 1
235000005074 zinc chloride Nutrition 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- G—PHYSICS
- G11—INFORMATION STORAGE
- G11C—STATIC STORES
- G11C5/00—Details of stores covered by group G11C11/00
- G11C5/02—Disposition of storage elements, e.g. in the form of a matrix array
- G11C5/025—Geometric lay-out considerations of storage- and peripheral-blocks in a semiconductor storage device
- G—PHYSICS
- G11—INFORMATION STORAGE
- G11C—STATIC STORES
- G11C7/00—Arrangements for writing information into, or reading information out from, a digital store
- G11C7/10—Input/output [I/O] data interface arrangements, e.g. I/O data control circuits, I/O data buffers
- G11C7/1048—Data bus control circuits, e.g. precharging, presetting, equalising

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Microelectronics & Electronic Packaging (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

NO19992895A 1996-12-20 1999-06-14 Substituerte dihydroindolderivater, farmasoytiske sammensetninger inneholdende dem og deres anvendelse. NO318978B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DK151496		1996-12-20
PCT/DK1997/000587 WO1998028293A1 (en)	1996-12-20	1997-12-19	Indane or dihydroindole derivatives

Publications (3)

Publication Number	Publication Date
NO992895D0 NO992895D0 (no)	1999-06-14
NO992895L NO992895L (no)	1999-08-13
NO318978B1 true NO318978B1 (no)	2005-05-30

Family

ID=8105631

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO19992895A NO318978B1 (no)	1996-12-20	1999-06-14	Substituerte dihydroindolderivater, farmasoytiske sammensetninger inneholdende dem og deres anvendelse.
NO20044514A NO20044514L (no)	1996-12-20	2004-10-21	Indan- eller dihydroindolderivater

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20044514A NO20044514L (no)	1996-12-20	2004-10-21	Indan- eller dihydroindolderivater

Country Status (27)

Country	Link
US (3)	US6262087B1 (is)
EP (1)	EP0946542B1 (is)
JP (1)	JP3251300B2 (is)
KR (1)	KR100432297B1 (is)
CN (3)	CN1244558C (is)
AR (1)	AR008545A1 (is)
AT (1)	ATE225784T1 (is)
AU (1)	AU731243B2 (is)
BG (1)	BG63968B1 (is)
BR (1)	BR9714039A (is)
CZ (1)	CZ297416B6 (is)
DE (1)	DE69716296T2 (is)
DK (1)	DK0946542T3 (is)
EA (1)	EA002158B1 (is)
ES (1)	ES2185058T3 (is)
HU (1)	HUP0000079A3 (is)
IL (1)	IL130133A (is)
IS (1)	IS2018B (is)
NO (2)	NO318978B1 (is)
NZ (1)	NZ335973A (is)
PL (1)	PL188418B1 (is)
PT (1)	PT946542E (is)
SK (1)	SK283678B6 (is)
TR (1)	TR199901407T2 (is)
UA (1)	UA66778C2 (is)
WO (1)	WO1998028293A1 (is)
ZA (1)	ZA9711376B (is)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA9711376B (en)	1996-12-20	1998-07-21	Lundbeck & Co As H	Indole or dihydroindole derivatives
TWI242011B (en) *	1997-03-31	2005-10-21	Eisai Co Ltd	1,4-substituted cyclic amine derivatives
PT1068199E (pt) *	1998-04-08	2003-02-28	Wyeth Corp	N-ariloxietil-indoli-alquilaminas para o tratamento da depressao
US6150533A (en) *	1998-04-08	2000-11-21	American Home Products Corp.	N-aryloxyethyl-indoly-alkylamines for the treatment of depression
TW528754B (en) *	1998-04-29	2003-04-21	Wyeth Corp	Indolyl derivatibes as serotonergic agents
US6204274B1 (en)	1998-04-29	2001-03-20	American Home Products Corporation	Indolyl derivatives as serotonergic agents
WO1999064044A1 (en) *	1998-06-08	1999-12-16	Advanced Medicine, Inc.	Novel therapeutic agents that modulate 5-ht receptors
US6541669B1 (en) *	1998-06-08	2003-04-01	Theravance, Inc.	β2-adrenergic receptor agonists
WO1999064045A1 (en) *	1998-06-08	1999-12-16	Advanced Medicine, Inc.	Novel therapeutic agents for membrane transporters
JP2003521443A (ja) *	1998-06-19	2003-07-15	ハー・ルンドベック・アクチエゼルスカベット	４，５，６及び７−インドール及びインドリン誘導体、その製造方法及びその使用方法
HK1044339A1 (zh)	1998-06-19	2002-10-18	H‧隆德贝克有限公司	4，5，6和7-吲及二氢吲衍生物，它们的制备和应用
EP0982030A3 (en)	1998-08-17	2000-05-10	Pfizer Products Inc.	2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands
AR020773A1 (es) *	1998-10-16	2002-05-29	Duphar Int Res	Compuesto derivados de 3-(tetrahidropiridin-4-il)indol, metodo para prepararlo, una composicion farmaceutica que los contiene, metodo para preparar dicha composicion y uso del compuesto
EP1140886B1 (en)	1998-12-23	2003-04-02	H. Lundbeck A/S	Method for the preparation of 5-cyanophthalide
KR100604156B1 (ko)	1999-04-14	2006-07-25	하. 룬트벡 아크티에 셀스카브	시탈로프람의 제조방법
JP2002544223A (ja) *	1999-05-12	2002-12-24	ソルベイ・フアーマシユーチカルズ・ベー・ブイ	精神病性障害の治療方法
AU5487300A (en) *	1999-06-14	2001-01-02	Neurogen Corporation	Benzylpiperazinyl-indolinylethanones
US6355644B1 (en)	1999-06-14	2002-03-12	Neurogen Corporation	Benzylpiperazinyl-indolinylethanones
WO2000078716A1 (en) *	1999-06-24	2000-12-28	Toray Industries, Inc.	α1B-ADRENERGIC RECEPTOR ANTAGONISTS
CZ298533B6 (cs)	1999-08-23	2007-10-31	Solvay Pharmaceuticals B. V.	Deriváty fenylpiperazinu, zpusob jejich prípravy a farmaceutické prostredky s jejich obsahem
US6476051B2 (en)	1999-12-17	2002-11-05	Bristol-Myers Squibb Company	Antipsychotic heterocycle compounds
UA74830C2 (en) *	2000-06-14	2006-02-15	Lundbeck & Co As H	Indole derivatives being useful for the treatment of cns disorders, a pharmaceutical composition and a method for the treatment of diseases
AR028685A1 (es)	2000-06-14	2003-05-21	Lundbeck & Co As H	Derivados de indol
SI1294710T1 (en) *	2000-06-14	2005-10-31	H. Lundbeck A/S	Indole derivatives useful for the treatment of cns disorders
MXPA02012506A (es) *	2000-06-29	2003-04-25	Lundbeck & Co As H	Derivados de indol utiles para el tratamiento de enfermedades del sistema nervioso central.
IL144817A0 (en)	2000-08-18	2002-06-30	Lundbeck & Co As H	Method for the preparation of citalopram
AR032712A1 (es)	2001-02-21	2003-11-19	Solvay Pharm Bv	Un mesilato de derivados de fenilpiperazina y composiciones farmaceuticas que lo contienen
AR033287A1 (es) *	2001-05-09	2003-12-10	Lundbeck & Co As H	Tratamiento del adhd
WO2003080050A1 (en) *	2002-03-27	2003-10-02	H. Lundbeck A/S	The use of 3-[1-[2-(1-acetyl-2,3-dihydro-1h-indol-3-yl)ethyl]-3,6-dihydro-2h-pyridin-4-yl]-6-chloro-1h-indole or its enantiomers for the treatment of diseases and disorders responsive to 5-ht (serotonin) re-uptake inhibition
WO2003102097A1 (en) *	2002-05-31	2003-12-11	H. Lundbeck A/S	The hydrochloride of (s)-(+)-3-[1-[2-(1-acetyl-2,3-dihydro-1h-indol-3-yl)ethyl]-1,2,3,6-tetrahydropyridin-4-yl]-6-chloro-1h-indole
AU2003243930A1 (en) *	2002-07-05	2004-01-23	H. Lundbeck A/S	Pharmaceutical composition comprising (s)-(+)-3-(1-(2-(1-acetyl-2,3-dihydro-1h-indol-3-yl)ethyl)-1,2,3,6-tetrahydropyridin-4-yl)-6-chloro-1h-indole
WO2004020437A1 (en) *	2002-08-29	2004-03-11	H. Lundbeck A/S	S-(+)-3-{1-[2-(2,3-dihydro-1h-indol-3-yl)ethyl]-3,6-dihydro-2h-pyridin-4-yl}-6-chloro-1h-indole and acid addition salts thereof
WO2004080407A2 (en) *	2003-03-07	2004-09-23	Predix Pharmaceuticals Holdings, Inc.	New serotonin modulating compounds and uses therefor
US20070265300A1 (en) *	2004-05-11	2007-11-15	Egis Gyogyszergyar Rt.	Pyridine Derivatives of Alkyl Oxindoles as 5-Ht7 Receptor Active Agents
ATE537153T1 (de) *	2004-09-09	2011-12-15	Merck Sharp & Dohme	Arylspirolactamverbindungen als antagonisten des cgrp-rezeptors
CN101084225B (zh) *	2004-11-26	2011-03-02	詹森药业有限公司	具有改良的抗精神病和抗焦虑活性的异噁唑啉-吲哚衍生物
TW200800960A (en) *	2005-08-17	2008-01-01	Lundbeck & Co As H	Novel 2,3-dihydroindole compounds
US7544685B2 (en)	2005-08-17	2009-06-09	H. Lundbeck A/S	2,3-dihydroindole compounds
JP2009515833A (ja) *	2005-10-24	2009-04-16	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	３−ピペリジン−４−イル−インドールｏｒｌ−１受容体モジュレーター
WO2008015516A1 (en) *	2006-07-28	2008-02-07	Pfizer Products Inc.	Fused tricyclic heterocycles for the treatment of schizophrenia
ES2375417T3 (es) *	2006-11-28	2012-02-29	Valeant Pharmaceuticals International	Análogos 1,4-diamino bicíclicos de retigabina como moduladores de los canales de potasio.
PL395469A1 (pl)	2011-06-29	2013-01-07	Adamed Spólka Z Ograniczona Odpowiedzialnoscia	Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego
US9951038B2 (en)	2012-12-27	2018-04-24	Purdue Pharma L.P.	Quinazolin-4(3H)-one-type piperidine compounds and uses thereof
WO2014102588A2 (en) *	2012-12-27	2014-07-03	Purdue Pharma L.P.	Indole and indoline-type piperidine compounds and uses thereof
EP3866927A4 (en)	2018-10-17	2022-07-27	Nikang Therapeutics, Inc.	Indane derivatives as hypoxia inducible factor-2(alpha) inhibitors
GB201919213D0 (en) *	2019-12-23	2020-02-05	Ucb Biopharma Sprl	Dihydrocyclopenta-Isoquinoline-Sulfanamide derivatives compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE81123T1 (de) *	1987-11-20	1992-10-15	Hoechst Roussel Pharma	3-(4(1-substituierte-4-piperazinyl)butyl>-4thiazolidinone, verfahren zu deren herstellung und ihre anwendung als arzneimittel.
FR2654104B1 (fr)	1989-11-07	1992-01-03	Adir	Nouveaux derives du 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
TW199152B (is)	1990-11-01	1993-02-01	Takeda Pharm Industry Co Ltd
FR2670491B1 (fr)	1990-12-14	1993-02-05	Adir	Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les renfermant.
WO1994021627A1 (en)	1993-03-18	1994-09-29	Merck Sharp & Dohme Limited	Indole derivatives as dopamine d4 antagonists
GB9305641D0 (en)	1993-03-18	1993-05-05	Merck Sharp & Dohme	Therapeutic agents
DE4414113A1 (de) *	1994-04-22	1995-10-26	Merck Patent Gmbh	3-Indolylpiperidine
CA2188949A1 (en)	1994-04-28	1995-11-09	Janusz Jozef Kulagowski	Benzofuran derivatives as d4 receptor antagonists
ZA954689B (en) *	1994-06-08	1996-01-29	Lundbeck & Co As H	4-Aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) piperidines tetrahydropyridines or piperazines
ZA9711376B (en)	1996-12-20	1998-07-21	Lundbeck & Co As H	Indole or dihydroindole derivatives
JP2003521443A (ja) *	1998-06-19	2003-07-15	ハー・ルンドベック・アクチエゼルスカベット	４，５，６及び７−インドール及びインドリン誘導体、その製造方法及びその使用方法

1997
- 1997-12-18 ZA ZA9711376A patent/ZA9711376B/xx unknown
- 1997-12-19 PL PL97334011A patent/PL188418B1/pl not_active IP Right Cessation
- 1997-12-19 CN CNB031088511A patent/CN1244558C/zh not_active Expired - Fee Related
- 1997-12-19 US US09/331,560 patent/US6262087B1/en not_active Expired - Fee Related
- 1997-12-19 IL IL13013397A patent/IL130133A/xx not_active IP Right Cessation
- 1997-12-19 AT AT97949998T patent/ATE225784T1/de not_active IP Right Cessation
- 1997-12-19 PT PT97949998T patent/PT946542E/pt unknown
- 1997-12-19 BR BR9714039-2A patent/BR9714039A/pt not_active Application Discontinuation
- 1997-12-19 HU HU0000079A patent/HUP0000079A3/hu unknown
- 1997-12-19 DK DK97949998T patent/DK0946542T3/da active
- 1997-12-19 ES ES97949998T patent/ES2185058T3/es not_active Expired - Lifetime
- 1997-12-19 UA UA99074138A patent/UA66778C2/uk unknown
- 1997-12-19 CN CNB971818134A patent/CN1146556C/zh not_active Expired - Fee Related
- 1997-12-19 SK SK813-99A patent/SK283678B6/sk not_active IP Right Cessation
- 1997-12-19 TR TR1999/01407T patent/TR199901407T2/xx unknown
- 1997-12-19 KR KR10-1999-7005622A patent/KR100432297B1/ko not_active Expired - Fee Related
- 1997-12-19 JP JP52826298A patent/JP3251300B2/ja not_active Expired - Fee Related
- 1997-12-19 DE DE69716296T patent/DE69716296T2/de not_active Expired - Fee Related
- 1997-12-19 AR ARP970106065A patent/AR008545A1/es active IP Right Grant
- 1997-12-19 CZ CZ0222799A patent/CZ297416B6/cs not_active IP Right Cessation
- 1997-12-19 EP EP97949998A patent/EP0946542B1/en not_active Expired - Lifetime
- 1997-12-19 CN CNB031088503A patent/CN1282644C/zh not_active Expired - Fee Related
- 1997-12-19 EA EA199900581A patent/EA002158B1/ru not_active IP Right Cessation
- 1997-12-19 AU AU53109/98A patent/AU731243B2/en not_active Ceased
- 1997-12-19 NZ NZ335973A patent/NZ335973A/xx unknown
- 1997-12-19 WO PCT/DK1997/000587 patent/WO1998028293A1/en not_active Ceased
1999
- 1999-05-28 IS IS5061A patent/IS2018B/is unknown
- 1999-06-14 NO NO19992895A patent/NO318978B1/no not_active IP Right Cessation
- 1999-07-07 BG BG103561A patent/BG63968B1/bg unknown
2001
- 2001-03-21 US US09/814,037 patent/US6352988B2/en not_active Expired - Fee Related
- 2001-03-21 US US09/813,480 patent/US6552044B2/en not_active Expired - Fee Related
2004
- 2004-10-21 NO NO20044514A patent/NO20044514L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CZ297416B6 (cs)	2006-12-13
NO20044514L (no)	1999-08-13
US6552044B2 (en)	2003-04-22
US20010021777A1 (en)	2001-09-13
WO1998028293A1 (en)	1998-07-02
EP0946542A1 (en)	1999-10-06
ZA9711376B (en)	1998-07-21
DE69716296T2 (de)	2003-09-11
AU731243B2 (en)	2001-03-29
PT946542E (pt)	2003-02-28
NO992895D0 (no)	1999-06-14
CN1515551A (zh)	2004-07-28
IS5061A (is)	1999-05-28
UA66778C2 (uk)	2004-06-15
EA002158B1 (ru)	2001-12-24
NZ335973A (en)	2000-11-24
PL188418B1 (pl)	2005-01-31
PL334011A1 (en)	2000-01-31
US6352988B2 (en)	2002-03-05
DK0946542T3 (da)	2003-02-10
HUP0000079A3 (en)	2002-11-28
HUP0000079A2 (hu)	2001-10-28
ES2185058T3 (es)	2003-04-16
EA199900581A1 (ru)	2000-04-24
KR20000069621A (ko)	2000-11-25
SK81399A3 (en)	1999-12-10
CN1244558C (zh)	2006-03-08
CN1495165A (zh)	2004-05-12
JP2000513731A (ja)	2000-10-17
DE69716296D1 (de)	2002-11-14
CN1146556C (zh)	2004-04-21
JP3251300B2 (ja)	2002-01-28
NO992895L (no)	1999-08-13
EP0946542B1 (en)	2002-10-09
US6262087B1 (en)	2001-07-17
SK283678B6 (sk)	2003-11-04
IS2018B (is)	2005-06-15
TR199901407T2 (xx)	1999-08-23
HK1025775A1 (en)	2000-11-24
IL130133A (en)	2005-08-31
KR100432297B1 (ko)	2004-05-20
BR9714039A (pt)	2000-05-09
BG63968B1 (bg)	2003-08-29
CZ222799A3 (cs)	1999-12-15
IL130133A0 (en)	2000-06-01
AU5310998A (en)	1998-07-17
AR008545A1 (es)	2000-01-19
CN1282644C (zh)	2006-11-01
CN1246117A (zh)	2000-03-01
ATE225784T1 (de)	2002-10-15
US20010020095A1 (en)	2001-09-06
BG103561A (en)	2000-06-30

Publication	Publication Date	Title
NO318978B1 (no)	2005-05-30	Substituerte dihydroindolderivater, farmasoytiske sammensetninger inneholdende dem og deres anvendelse.
AU765317C (en)	2004-05-20	4,5,6 and 7-indole and indoline derivatives, their preparation and use
US7544685B2 (en)	2009-06-09	2,3-dihydroindole compounds
US5789404A (en)	1998-08-04	3-substituted 1-arylindole compounds
NO323236B1 (no)	2007-02-05	Indolderivater, deres anvendelse og farmasoytiske sammensetninger omfattende disse
SK19412000A3 (sk)	2001-07-10	Substituované 4,5,6 a 7-indolové alebo indolínové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
CA2275299C (en)	2003-12-16	Indane or dihydroindole derivatives
MXPA99005532A (en)	2000-01-21	Indane or dihydroindole derivatives
CN101243075A (zh)	2008-08-13	新颖的2,3-二氢吲哚化合物
US6436940B2 (en)	2002-08-20	Indane or dihydroindole derivatives
HK1123550A (en)	2009-06-19	Novel 2,3-dihydroindole compounds
NO318610B1 (no)	2005-04-18	Indol og 2,3-dihydroindolderivater, deres fremstilling og anvendelse

Legal Events

Date	Code	Title	Description
2010-07-19	MM1K	Lapsed by not paying the annual fees